|1.||Kozel, Thomas R: 3 articles (08/2011 - 04/2003)|
|2.||Levitz, Stuart M: 3 articles (11/2006 - 01/2002)|
|3.||Casadevall, A: 3 articles (09/2006 - 01/2000)|
|4.||Dadachova, E: 2 articles (09/2015 - 09/2006)|
|5.||Casadevall, Arturo: 2 articles (06/2007 - 04/2003)|
|6.||Yauch, Lauren E: 2 articles (11/2006 - 12/2005)|
|7.||Bistoni, Francesco: 2 articles (11/2004 - 04/2003)|
|8.||Vecchiarelli, Anna: 2 articles (11/2004 - 04/2003)|
|9.||Cutler, J E: 2 articles (08/2001 - 01/2000)|
|10.||Han, Y: 2 articles (08/2001 - 01/2000)|
01/15/2001 - "Defined Abs to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been shown to be protective against experimental cryptococcosis. "
09/01/2015 - "We targeted murine cryptococcosis with a mAb to the Cryptococcus neoformans capsular glucuronoxylomannan labeled with Bismuth-213 ((213)Bi) or Rhenium-188 ((188)Re). "
08/01/2011 - "Immunoassay for detection of glucuronoxylomannan (GXM), the major capsular polysaccharide of Cryptococcus neoformans, is an important tool for diagnosis of cryptococcosis. "
11/01/2006 - "Glucuronoxylomannan (GXM), the major component of the capsule, is a high-molecular-weight polysaccharide that is shed during cryptococcosis and can persist in patients after successful antifungal therapy. "
09/01/2006 - "We have recently demonstrated the feasibility of using RIT for treating murine cryptococcosis using a monoclonal antibody to Crypto-coccus neoformans capsular glucuronoxylomannan labeled with Bismuth-213 or Rhenium-188. "
01/21/2013 - "The efficiency of the approach to the quantification of the inhibition effect of polysaccharide glucuronoxylomannan (GXM) on the infection efficiency of the tobacco mosaic virus (TMV) was investigated using advanced serological approaches based on label-free surface plasmon resonance technique. "
04/01/2003 - "Disseminated infections by the opportunistic yeast Cryptococcus neoformans are characterized by accumulation in tissues of glucuronoxylomannan (GXM), the major component of the capsular polysaccharide. "
08/01/2001 - "In contrast to cellular heterogeneity, the epitope recognized by a protective mAb on the capsular glucuronoxylomannan (GXM) was found at all times of infection. "
02/01/1998 - "mAbs to glucuronoxylomannan (GXM), the predominant constituent of the polysaccharide capsule are protective in a variety of murine infection models. "
09/01/1996 - "Administration of MoAbs to Cryptococcus neoformans capsular glucuronoxylomannan (GXM) can alter the course of infection in mouse models. "
10/01/1998 - "Does the capsule component of the Cryptococcus neoformans glucuronoxylomannan impair transendothelial migration of leukocytes in patients with cryptococcal meningitis?"
05/01/1995 - "Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis."
01/01/1998 - "On the basis of the clinical observation that the cerebrospinal fluid (CSF) of patients with cryptococcal meningitis contains high levels of the chemokine interleukin (IL)-8 but few polymorphonuclear leukocytes (PMNL), the production of IL-8 by cultured brain glial cells after stimulation with two serotypes of cryptococcal capsular polysaccharide glucuronoxylomannan (GXM) was studied, followed by an assessment of the effect of GXM on PMNL migration toward IL-8. "
09/02/1992 - "Cryptococcus neoformans, the etiologic agent of cryptococcal meningoencephalitis, produces glucuronoxylomannan (GXM) as the major capsule component. "
01/01/2010 - "The paper gives a case of successful treatment for cryptococcal meningoencephalitis in the presence of agranulocytosis, the diagnosis of which is based on the detection of abnormal MR signal foci by magnetic resonance imaging and identification of the cryptococcal antigen-glucuronoxylomannan in spinal fluid."
|3.||Immunoglobulin G (IgG)
|5.||Tetanus Toxoid (Vaccine, Tetanus)
|6.||Immunoglobulin M (IgM)
|8.||Proliferating Cell Nuclear Antigen (PCNA)
|10.||Interleukin-8 (Interleukin 8)